This is the current release of the guideline.

The table below summarizes the American Cancer Society (ACS) recommendations for human papillomavirus (HPV) vaccines.

Summary of ACS Recommendations for HPV Vaccine Use to Prevent Cervical Cancer and Its Precursors

*Insufficient evidence of benefit in women aged 19 to 26 years refers to (1) clinical trial data in women with an average of 2, and not more than 4, lifetime sexual partners, indicating a limited reduction in the overall incidence of cervical intraepithelial neoplasia (CIN)2/3; (2) the absence of efficacy data for the prevention of HPV16/18-related CIN2/3 in women who have had more than 4 lifetime sexual partners; and (3) the lack of cost-effectiveness analyses for vaccination in this age group.

To attain the greatest impact on cervical cancer prevention, the ACS provides the following supporting recommendations:

Screening

• It is critical that women, whether vaccinated or not, continue screening according to current ACS early detection guidelines.
• A preventive health care visit in which vaccination is discussed or offered represents an appropriate opportunity to offer Pap screening to sexually active patients.
• HPV testing before initiating vaccination is not recommended.

Vaccine Implementation and Utilization

• Public health and policy efforts are needed to ensure access and encourage high HPV vaccine coverage for all racial, ethnic, and socioeconomic groups, particularly for females of color, immigrants, those living in rural areas, low-income and uninsured females, and others who have limited access to health care services.
• Strategies should be implemented to maximize adherence to vaccination recommendations, including coadministration with other recommended adolescent vaccines, once sufficient safety data are available.
• The use of noncomprehensive visits (e.g., minor illness visits, camp/sports physical visits) and alternative vaccination sites for adolescents unable to access comprehensive preventive care is encouraged.

Education

• There is a critical need for education of providers, policy-makers, parents, adolescents, and young women about cervical cancer prevention and early detection, including the need for regular screening even after vaccination.

None provided

The type of supporting evidence is not specifically stated for each recommendation.

Not applicable: The guideline was not adapted from another source.

2007 Jan

American Cancer Society - Disease Specific Society

American Cancer Society

American Cancer Society Guideline Panel

Panel Members: Debbie Saslow, PhD; Philip E. Castle, PhD, MPH; J. Thomas Cox, MD; Diane D. Davey, MD; Mark H. Einstein, MD, MS; Daron G. Ferris, MD; Sue J. Goldie, MD, MPH; Diane M. Harper, MD, MPH, MS; Walter Kinney, MD; Anna-Barbara Moscicki, MD; Kenneth L. Noller, MD; Cosette M. Wheeler, PhD; Terri Ades, RN, MS, AOCN; Kimberly S. Andrews; Mary K. Doroshenk, MA; Kelly Green Kahn; Christy Schmidt; Omar Shafey, PhD, MPH; Robert A. Smith, PhD; Edward E. Partridge, MD (for the Gynecologic Cancer Advisory Group); Francisco Garcia, MD, MPH

Workgroup members were asked to disclose relationships, including potential financial conflicts of interest, with vaccine manufacturers or trials. The following was disclosed: F. Garcia participated in an expert panel for GlaxoSmithKline (GSK) for an unrelated immune therapeutic class of agents; C. Cohen is a paid speaker for Merck; T. Cox is a paid member of the Merck Data Safety and Monitoring Committee and received an honorarium for serving on one management advisory board for GSK; D. Davey serves on the working group of the NCI-sponsored trial of GSK vaccine in Costa Rica; M. Einstein has received research support from GSK for a nonvaccine-related activity and serves on the speaker's bureau for Merck, but receives no salary support or honorarium; D. Ferris receives research support for vaccine trials from Merck and GSK and serves as a colposcopy quality control consultant to both Merck and GSK and on the Merck medical advisory board; D. Harper serves on the study planning committee for Merck and GSK and is a clinical site PI for GSK; A. Moscicki serves on Merck's speaker's bureau and adolescent advisory board and is a local PI on the GSK vaccine trial; E. Partridge received an honorarium for a one-day advisory meeting for Merck and is a PI for a clinical study site for Merck; C. Wheeler receives research support for vaccine trials from Merck and GSK; D. Solomon is a medical monitor for the NCI-sponsored trial of GSK vaccine in Costa Rica.

This is the current release of the guideline.

None available

This NGC summary was completed by ECRI Institute on January 31, 2008. The information was verified by the guideline developer on February 29, 2008.

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.